Catalyst Historical Income Statement

CPRX Stock

USD 22.07 0.27 1.21%

Historical analysis of Catalyst Pharmaceuticals income statement accounts such as Other Operating Expenses of 327 M, Operating Income of 91.2 M or Ebit of 91.2 M can show how well Catalyst Pharmaceuticals performed in making a profits. Evaluating Catalyst Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Catalyst Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Catalyst Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Catalyst Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.

About Catalyst Income Statement Analysis

Catalyst Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Catalyst Pharmaceuticals shareholders. The income statement also shows Catalyst investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Catalyst Pharmaceuticals Income Statement Chart

At this time, Catalyst Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 49.4 M in 2024, whereas Net Interest Income is likely to drop slightly above 1 M in 2024.

Other Operating Expenses Ebit Research Development Total Operating Expenses Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Catalyst Pharmaceuticals. It is also known as Catalyst Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Catalyst Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Catalyst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Catalyst Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Catalyst Stock please use our How to Invest in Catalyst Pharmaceuticals guide.At this time, Catalyst Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Selling General Administrative is likely to rise to about 49.4 M in 2024, whereas Net Interest Income is likely to drop slightly above 1 M in 2024.

	2023	2024 (projected)
Reconciled Depreciation	24.4M	25.6M
Net Interest Income	1.8M	1.0M

Reconciled Depreciation Net Interest Income

Catalyst Pharmaceuticals income statement Correlations

	Interest Expense	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Net Income	Income Tax Expense	Depreciation And Amortization	Selling General Administrative	Total Other Income Expense Net	Total Revenue	Gross Profit	Cost Of Revenue	Net Income From Continuing Ops	Non Operating Income Net Other	Interest Income	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Interest Expense		0.92	0.86	0.86	0.87	0.91	0.9	0.88	0.81	0.6	0.81	0.91	0.91	0.94	0.94	0.93	0.78	0.88	0.81	0.68	0.82	0.88
Other Operating Expenses	0.92		0.82	0.82	0.98	0.9	1.0	0.84	0.76	0.6	0.95	0.91	0.95	0.98	0.98	0.99	0.71	0.79	0.76	0.6	0.96	0.99
Operating Income	0.86	0.82		1.0	0.69	0.99	0.78	1.0	0.96	0.53	0.65	0.84	0.73	0.91	0.92	0.8	0.95	0.71	0.8	0.73	0.65	0.81
Ebit	0.86	0.82	1.0		0.69	0.99	0.78	1.0	0.96	0.53	0.65	0.83	0.73	0.91	0.92	0.8	0.95	0.7	0.79	0.73	0.65	0.81
Research Development	0.87	0.98	0.69	0.69		0.79	0.99	0.71	0.62	0.6	0.98	0.86	0.94	0.93	0.91	0.97	0.57	0.75	0.67	0.49	0.98	0.96
Ebitda	0.91	0.9	0.99	0.99	0.79		0.87	0.99	0.94	0.58	0.76	0.87	0.82	0.96	0.97	0.88	0.92	0.75	0.79	0.69	0.77	0.9
Total Operating Expenses	0.9	1.0	0.78	0.78	0.99	0.87		0.8	0.72	0.6	0.97	0.9	0.95	0.97	0.96	0.98	0.68	0.78	0.74	0.57	0.97	0.99
Income Before Tax	0.88	0.84	1.0	1.0	0.71	0.99	0.8		0.96	0.54	0.67	0.85	0.76	0.92	0.93	0.82	0.95	0.73	0.8	0.72	0.68	0.83
Net Income	0.81	0.76	0.96	0.96	0.62	0.94	0.72	0.96		0.29	0.57	0.8	0.66	0.85	0.87	0.73	1.0	0.64	0.81	0.76	0.58	0.76
Income Tax Expense	0.6	0.6	0.53	0.53	0.6	0.58	0.6	0.54	0.29		0.59	0.53	0.62	0.6	0.6	0.64	0.25	0.58	0.34	0.23	0.59	0.59
Depreciation And Amortization	0.81	0.95	0.65	0.65	0.98	0.76	0.97	0.67	0.57	0.59		0.77	0.93	0.9	0.88	0.94	0.52	0.69	0.55	0.36	1.0	0.96
Selling General Administrative	0.91	0.91	0.84	0.83	0.86	0.87	0.9	0.85	0.8	0.53	0.77		0.86	0.92	0.93	0.89	0.78	0.83	0.92	0.8	0.78	0.84
Total Other Income Expense Net	0.91	0.95	0.73	0.73	0.94	0.82	0.95	0.76	0.66	0.62	0.93	0.86		0.92	0.91	0.95	0.62	0.91	0.7	0.52	0.93	0.92
Total Revenue	0.94	0.98	0.91	0.91	0.93	0.96	0.97	0.92	0.85	0.6	0.9	0.92	0.92		1.0	0.97	0.82	0.8	0.8	0.66	0.9	0.97
Gross Profit	0.94	0.98	0.92	0.92	0.91	0.97	0.96	0.93	0.87	0.6	0.88	0.93	0.91	1.0		0.96	0.84	0.79	0.82	0.68	0.88	0.96
Cost Of Revenue	0.93	0.99	0.8	0.8	0.97	0.88	0.98	0.82	0.73	0.64	0.94	0.89	0.95	0.97	0.96		0.68	0.8	0.77	0.6	0.95	0.97
Net Income From Continuing Ops	0.78	0.71	0.95	0.95	0.57	0.92	0.68	0.95	1.0	0.25	0.52	0.78	0.62	0.82	0.84	0.68		0.62	0.8	0.77	0.53	0.71
Non Operating Income Net Other	0.88	0.79	0.71	0.7	0.75	0.75	0.78	0.73	0.64	0.58	0.69	0.83	0.91	0.8	0.79	0.8	0.62		0.73	0.6	0.7	0.74
Interest Income	0.81	0.76	0.8	0.79	0.67	0.79	0.74	0.8	0.81	0.34	0.55	0.92	0.7	0.8	0.82	0.77	0.8	0.73		0.94	0.56	0.7
Net Interest Income	0.68	0.6	0.73	0.73	0.49	0.69	0.57	0.72	0.76	0.23	0.36	0.8	0.52	0.66	0.68	0.6	0.77	0.6	0.94		0.37	0.54
Reconciled Depreciation	0.82	0.96	0.65	0.65	0.98	0.77	0.97	0.68	0.58	0.59	1.0	0.78	0.93	0.9	0.88	0.95	0.53	0.7	0.56	0.37		0.96
Selling And Marketing Expenses	0.88	0.99	0.81	0.81	0.96	0.9	0.99	0.83	0.76	0.59	0.96	0.84	0.92	0.97	0.96	0.97	0.71	0.74	0.7	0.54	0.96

Click cells to compare fundamentals

Catalyst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Ebit
Net Income From Continuing Ops	+ 1.0	Net Income
Reconciled Depreciation	+ 1.0	Depreciation And Amortization

High Negative Relationship

Not Found

Catalyst Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	1.9M	1.5M	474K	4.1M	4.7M	5.0M
Other Operating Expenses	70.5M	77.8M	88.4M	112.4M	311.4M	327.0M
Operating Income	31.8M	41.3M	52.4M	101.8M	86.8M	91.2M
Ebit	31.8M	41.3M	52.4M	101.8M	86.8M	91.2M
Research Development	18.8M	16.5M	16.9M	19.8M	93.2M	97.8M
Ebitda	32.1M	42.2M	52.6M	103.1M	119.7M	125.7M
Total Operating Expenses	55.7M	60.7M	66.6M	78.0M	259.4M	272.4M
Income Before Tax	33.4M	41.9M	52.7M	104.7M	94.5M	99.2M
Net Income	31.9M	75.0M	39.5M	83.1M	71.4M	75.0M
Income Tax Expense	1.5M	(33.1M)	13.2M	21.6M	23.1M	24.3M
Depreciation And Amortization	297.7K	885.3K	192K	1.2M	32.9M	34.5M
Selling General Administrative	36.9M	20.7M	23.5M	28.7M	47.0M	49.4M
Total Other Income Expense Net	1.6M	586.9K	282K	2.9M	7.7M	8.1M
Total Revenue	102.3M	119.1M	140.8M	214.2M	398.2M	418.1M
Gross Profit	87.5M	102.0M	118.9M	179.8M	313.7M	329.4M
Cost Of Revenue	14.8M	17.0M	21.9M	34.4M	84.5M	88.8M
Net Income From Continuing Ops	31.9M	75.0M	39.5M	83.1M	62.0M	65.1M
Non Operating Income Net Other	1.3M	1.6M	282K	2.9M	3.3M	3.5M
Net Income Applicable To Common Shares	31.9M	75.0M	39.5M	83.1M	95.5M	100.3M
Tax Provision	1.5M	(33.1M)	13.2M	21.6M	18.8M	19.7M
Reconciled Depreciation	297.7K	885.3K	192K	1.2M	24.4M	25.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Catalyst Stock Analysis

When running Catalyst Pharmaceuticals' price analysis, check to measure Catalyst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Catalyst Pharmaceuticals is operating at the current time. Most of Catalyst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Catalyst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Catalyst Pharmaceuticals' price. Additionally, you may evaluate how the addition of Catalyst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Catalyst Historical Income Statement

About Catalyst Income Statement Analysis

Catalyst Pharmaceuticals Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Catalyst Pharmaceuticals income statement Correlations

Catalyst Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Catalyst Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for Catalyst Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY